ROCKVILLE, Md., Feb. 6, 2023
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that
three presentations on RGX-314 will be presented at the
Angiogenesis, Exudation, and Degeneration 2023 Conference taking
place virtually from February 10-11,
2023. New data will be presented from a Phase II bridging
study evaluating the pharmacodynamics, safety and efficacy of
RGX-314 delivered subretinally using cGMP material produced by the
REGENXBIO NAVXpress™ platform process to support future
commercialization.
The presentations will be as follows:
Presentation Title: Subretinal Delivery of RGX-314 for
Neovascular AMD: A Phase II Pharmacodynamic Study
Presenter: Charles C. Wykoff, M.D., PhD, Retina
Consultants of Texas
Date/Time: Saturday, February 11,
2023, 8:40 a.m. ET
Presentation Title: Long-Term Follow-Up of Durable
Subretinal RGX-314 Gene Therapy for Exudative AMD
Presenter: Allen C. Ho, M.D., Director of Retina
Research, Wills Eye Hospital, Mid Atlantic Retina
Date/Time: Saturday, February 11, 2023, 8:50 a.m. ET
Presentation Title: Suprachoroidal Therapy for Diabetic
Retinopathy
Presenter: Peter A. Campochiaro, M.D., Director,
Retinal Cell and Molecular Laboratory
Professor of Ophthalmology, John Hopkins
School of Medicine
Date/Time: Saturday, February 11, 2023, 10:40 a.m. ET
About REGENXBIO Inc.
REGENXBIO is a leading
clinical-stage biotechnology company seeking to improve lives
through the curative potential of gene therapy. REGENXBIO's NAV
Technology Platform, a proprietary adeno-associated virus (AAV)
gene delivery platform, consists of exclusive rights to more than
100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.
REGENXBIO and its third-party NAV Technology Platform Licensees are
applying the NAV Technology Platform in the development of a broad
pipeline of candidates, including late-stage and commercial
programs, in multiple therapeutic areas. REGENXBIO is committed to
a "5 x '25" strategy to progress five AAV Therapeutics from our
internal pipeline and licensed programs into pivotal-stage or
commercial products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-angiogenesis-exudation-and-degeneration-2023-conference-301739018.html
SOURCE REGENXBIO Inc.